Optimization of heroin conjugate vaccine performance in rodent models.

Animal / preclinicalNPJ vaccines· Jul 2026

Optimization of heroin conjugate vaccine performance in rodent models.

Essie Komla, Connor Whalen, Oscar B Torres … Gary R Matyas

Read paper

Addiction MedicineAnimal / preclinicalQ1IF 6.8

Heroin vaccine antibody response and protection lasted 54 weeks in animals.

Optimization of heroin conjugate vaccine performance in rodent models.

Essie Komla … Gary R Matyas

NPJ vaccines · Jul 2026

Background

Opioid use disorder (opioid use disorder) remains a global public health concern, exerting a significant economic burden on societies worldwide.

54

Results

54

weeks

protection held steady for over a year with no drop in antibodies

More results

In this study, multiple parameters to optimize the efficacy of the TT-6-AmHap heroin conjugate vaccine were investigated in mice and rats, focusing on dose optimization, hapten density, booster timing, and cross-reactivity with other prescription opioids.

More results

Immunization with TT-6-AmHap vaccine in combination with adjuvants ALF43 and Alhydrogel ® (ALFA), demonstrated a robust in-vivo efficacy across multiple opioid challenges including heroin, hydrocodone, and hydromorphone.

Notably, these repeat heroin challenges did not induce any measurable decline in antibody titers.

“

Conclusion

These findings support the continued development of hapten-based conjugate vaccines for opioid use disorder and demonstrate that an optimized vaccine can provide long-lasting protection against the antinociceptive effects of opioids in animals, laying the groundwork for future translational studies.

Optimization of heroin conjugate vaccine performance in rodent models.

Optimization of heroin conjugate vaccine performance in rodent models.

Related papers